Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that Michael
Hall, MB. BCh., has joined the company as senior vice president of
clinical development. Dr. Hall will lead Ironwood’s clinical research,
clinical development, clinical operations, biostatistics and
pharmacovigilance teams. In this role, he will oversee clinical trials
investigating additional appropriate populations for linaclotide, as
well as Ironwood’s pipeline of early development candidates.
Michael Hall, MB. BCh., senior vice president of clinical development, Ironwood Pharmaceuticals Inc. (Photo: Business Wire)
“Michael’s unique combination of drug development experience, deep
scientific knowledge, patient-oriented medical perspective, and proven
leadership capabilities will be of significant value in supporting our
clinical development activities,” said Mark Currie, Ph.D., senior vice
president, chief scientific officer, and president of research and
development at Ironwood. “We feel very fortunate to welcome Michael to
our team.”
Prior to joining Ironwood, Dr. Hall served as chief medical officer and
senior vice president at Repligen Corp., where he oversaw the
advancement of late-stage programs through registration application and
early-stage programs into the clinic. He previously served as vice
president of global clinical affairs at Shire Human Genetic Therapies,
where he led clinical research, clinical operations and biostatistics,
and he established a translational medicine group supporting the early
clinical and business development teams that was instrumental in the
in-licensing of multiple products. Dr. Hall previously held medical
affairs, pharmacovigilance and clinical positions at Novartis
Pharmaceuticals Corp. Prior to joining the pharmaceutical industry, Dr.
Hall worked at Hillbrow Hospital and Johannesburg General Hospital, both
in Johannesburg. He earned his MB. BCh. medical degree from the
University of Witwatersrand Medical School in Johannesburg.
“The discipline with which the team at Ironwood advances programs and
the degree to which they focus on science that addresses unmet needs of
patients were driving factors in my decision to join the company,” said
Dr. Hall. “I look forward to adding my clinical development and medical
expertise to the passionate and experienced team of pharmacologists and
business leaders at Ironwood.”
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is committed to the art and
science of making medicines, from discovery through commercialization.
We’re focused on three goals: transforming knowledge into medicines that
make a difference for patients, creating value that will inspire the
continued support of our fellow shareholders, and building a team that
passionately pursues excellence. Our first product, linaclotide, is
approved in the United States and Europe. Our pipeline priorities
include exploring further opportunities for linaclotide, leveraging our
deep expertise in functional gastrointestinal disorders, and advancing
programs in other areas such as allergic conditions, cardiovascular
disease, central nervous system disorders and other conditions defined
by patient symptoms. Ironwood was founded in 1998 and is headquartered
in Cambridge, Mass. Connect with us at www.ironwoodpharma.com
or on Twitter at www.twitter.com/ironwoodpharma
to learn more about Ironwood. Information that may be important to
investors will be routinely posted in both these locations.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130821005085/en/
Copyright Business Wire 2013